FrancophonIA/ELRC3.0 huggingface dataset:
English: - You will be sensitive to bright light for 48 hours after the infusion.
Croatian: - Ako primate Visudyne, biti ćete osjetljivi na svjetlost tijekom 48 sati nakon primjene lijeka.
English: 339 patients (225 verteporfin, 114 placebo) were enrolled in this study.
Croatian: U ispitivanje je uključeno 339 bolesnika (225 ih je primalo verteporfin, 114 je primalo placebo).
English: Patients should be under close medical supervision during the Visudyne infusion.
Croatian: Bolesnike treba pozorno pratiti tijekom infuzije Visudyneom.
English: Visudyne contains small amounts of butylated hydroxytoluene (E321), which may be irritant to eyes, skin and mucous membranes.
Croatian: Visudyne sadrži manje količine butilhidroksitoluena (E321), koji može nadražiti oči, kožu i sluznice.
English: Patients who receive Visudyne will become photosensitive for 48 hours after the infusion.
Croatian: Bolesnici koji primaju Visudyne osjetljivi su na svjetlost tijekom 48 sati nakon infuzije.
English: During that time, avoid exposure to direct sunlight, bright indoor lights such as in tanning salons, bright halogen lighting, high power lighting as used by surgeons or dentists, or light from light-emitting medical devices such as pulse oximeters (used to measure oxygen in blood).
Croatian: Za to vrijeme morate izbjegavati izlaganje izravnoj sunčevoj svjetlosti, jakoj sobnoj svjetlosti, poput one u solarijima, svjetlosti halogene svjetiljke, svjetlosti jakih svjetiljaka kakve koriste kirurzi i stomatolozi te svjetlosti medicinskih proizvoda koji emitiraju svjetlost, poput pulsnih oksimetara.
English: No effect on male or female fertility has been observed in rats following intravenous verteporfin doses of up to 10 mg/kg/day (approximately 60 and 40-fold human exposure at 6 mg/m based on AUCinf in male and female rats, respectively).
Croatian: Nisu zapaženi nikakvi učinci na plodnost mužjaka ili ženki štakora nakon intravenske primjene doza verteporfina od najviše 10 mg/kg/dan (približno 60 puta odnosno 40 puta veće od izloženosti u ljudi od 6 mg/m na temelju vrijednosti AUCinf u mužjaka odnosno ženki štakora).
English: The VIO study included patients with occult with no classic subfoveal CNV with a visual acuity score of 73-34 letters (20/40-20/200), and patients with lesions >4 MPS disc areas were to have baseline visual acuity <65 letters (<20/50).
Croatian: U ispitivanju VIO sudjelovali su bolesnici s prikrivenim, ali bez klasičnog subfovealnog CNV-a, s rezultatom vidne oštrine između 73 i 34 slova (20/40-20/200), i bolesnici s lezijama u >4 područja diskova u MPS-u koji su u početku morali imati vidnu oštrinu oka <65 slova (<20/50).
English: Visudyne contains small amounts of butylated hydroxytoluene (E321) This ingredient is irritant to eyes, skin and mucous membranes.
Croatian: Visudyne sadrži male količine butilhidroksitoluena (E321) Ovaj sastojak nadražuje oči, kožu i sluznicu.
English: • Infusion site side effects: as with other types of injections, some patients experienced blistering.
Croatian: • Nuspojave povezane s mjestom injiciranja: kao i s drugim vrstama injekcija, u nekih se bolesnika pojavljuju mjehurići.
English: Visudyne is indicated for the treatment of - adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or - adults with subfoveal choroidal neovascularisation secondary to pathological myopia.
Croatian: Visudyne je indiciran za liječenje: - odraslih bolesnika s eksudativnom (vlažnom) senilnom makularnom degeneracijom okarakteriziranom predominantno klasičnom subfovealnom neovaskularizacijom žilnice ili - odraslih bolesnika sa subfovealnom neovaskularizacijom žilnice izazvanom patološkom kratkovidnošću.
English: For a dose of 6 mg/m body surface (see section 4.2) dilute the required amount of Visudyne solution in dextrose 50 mg/ml (5%) solution for infusion to a final volume of 30 ml.
Croatian: Za dozu od 6 mg/m tjelesne površine (vidjeti dio 4.2), potrebnu količinu otopine Visudynea treba razrijediti s 5%-tnom (50 mg/ml) otopinom glukoze za infuziju do konačnog volumena od 30 ml.
English: No studies on the pharmacokinetics of verteporfin in patients with renal impairment are reported.
Croatian: Nema prijavljenih ispitivanja farmakokinetike verteporfina u bolesnika s oštećenjem bubrega.
English: Patients should be under close medical supervision during the Visudyne infusion and caution should be exercised when Visudyne treatment under general anaesthesia is considered.
Croatian: Tijekom infuzije Visudynea bolesnici moraju biti pod pažljivim liječničkim nadzorom, a nužan je oprez i pri davanju Visudynea bolesnicima u općoj anesteziji.
English: This study also included patients with classic containing CNV with a visual acuity score >70 letters (20/40).
Croatian: U ispitivanju su sudjelovali i bolesnici s klasičnim CNV-om i vidnom oštrinom >70 znakova (20/40).
English: It is recommended that, if you are given Visudyne, you do not breastfeed for 48 hours after administration.
Croatian: Preporučuje se da, ako primate Visudyne, nakon primjene lijeka prekinete dojenje na 48 sati.
English: Pregnancy and breast-feeding - There is very little experience of using Visudyne in pregnant women.
Croatian: - Ima vrlo malo iskustva o primjeni Visudynea u trudnica.
English: No clinical data on exposed pregnancies are available for verteporfin.
Croatian: Ne postoje klinički podaci o izloženosti verteporfinu u trudnoći.
English: For a dose of 6 mg/m body surface (the dose recommended for the treatment) dilute the required amount of Visudyne solution in dextrose 50 mg/ml (5 %) solution for infusion to a final volume of 30 ml.
Croatian: Za dozu od 6 mg/m tjelesne površine (doza preporučena za liječenje), potrebnu količinu otopine Visudynea treba razrijediti s 5%-tnom (50 mg/ml) otopinom glukoze za infuziju do konačnog volumena od 30 ml.
English: Visudyne is used for the treatment of predominantly classic choroidal neovascularisation in adults with age-related macular degeneration, and also for the treatment of all types of choroidal neovascularisation in adults with pathological myopia.
Croatian: Visudyne se koristi za liječenje uglavnom klasične neovaskularizacije žilnice u odraslih bolesnika sa senilnom maskularnom degeneracijom, kao i za liječenje svih vrsta neovaskularizacije žilnice u odraslih osoba s patološkom kratkovidnoošću.
English: If you have to go outdoors during daylight in the first 48 hours after treatment, you must protect your skin and eyes by wearing protective clothing and dark sunglasses.
Croatian: Morate li izaći na danje svjetlo unutar 48 sati nakon liječenja, oči morate zaštititi tamnim sunčanim naočalama, a kožu prikladnom odjećom.
English: A higher percentage of patients who received Visudyne, compared with those who received placebo, experienced adverse events (89.3% versus 82.5 %), associated adverse events (42.7% versus 18.4%) and events leading to discontinuation (6.2% versus 0.9%).
Croatian: Bolesnici koji su primali Visudyne, ako ih usporedimo s onima koji su primali placebo, u većem su postotku bilježili štetne događaje (89,3% u odnosu na 82,5%), povezane štetne događaje (42,7% u odnosu na 18,4%) i događaje koji su doveli do prekida terapije (6,2% u odnosu na 0,9%).
English: At month 12, the study did not show statistically significant results on the primary efficacy parameter (responder rate 49.3% versus 45.6%, p=0.517).
Croatian: Nakon 12 mjeseci, između dviju skupina nije uočena nikakva statistički značajna razlika s obzirom na primarni pokazatelj djelotvornosti (stopa bolesnika s odgovorom 49,3% u odnosu na 45,6%, p=0,517).
English: Both vasovagal and hypersensitivity reactions are associated with general symptoms such as syncope, sweating, dizziness, rash, dyspnoea, flushing, and changes in blood pressure and heart rate.
Croatian: I vazovagalne reakcije i reakcije preosjetljivosti povezane su s općim simptomima poput sinkope, znojenja, omaglice, osipa, dispneje, navale crvenila te promjena krvnog tlaka i pulsa.
English: • Eye disorders: bleeding of the retina or into the vitreous humour (the clear gel-like substance that fills the eyeball behind the lens), swelling or fluid retention in the retina and displacement of the retina in the treated eye.
Croatian: • Poremećaji oka: krvarenje mrežnice ili u tekućini u staklovini (prozirna tvar nalik gelu koja ispunjava očnu jabučicu iza leća), oticanje ili zadržavanje tekućine u mrežnici i odvajanje mrežnice u liječenom oku.
English: Chest pain, vasovagal reactions and hypersensitivity reactions related to Visudyne infusion have been reported.
Croatian: Zabilježeni su slučajevi boli u prsnom košu, vazovagalnih reakcija i reakcija preosjetljivosti vezano uz infuziju Visudynea.
English: Infusion-related chest pain
Croatian: Bol u prsnom košu povezana s infuzijom
English: Cases of anaphylactic reactions have been observed in patients receiving Visudyne.
Croatian: Zabilježeni su slučajevi anafilaktičkih reakcija u bolesnika koji su primali Visudyne.
English: It is important to tell your doctor if you are pregnant, if you think you may be pregnant or if you plan to become pregnant.
Croatian: Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
English: Nausea.
Croatian: Mučnina.
English: General symptoms can include headache, malaise, syncope, hyperhydrosis, dizziness, rash, urticaria, pruritus, dyspnoea, flushing, and changes in blood pressure and heart rate.
Croatian: Opći simptomi mogu uključivati glavobolju, malaksalost, sinkopu, znojenje, omaglicu, osip, urtikariju, pruritus, dispneju, navalu crvenila te promjene krvnoga tlaka i pulsa.
English: Visudyne 15 mg powder for solution for infusion
Croatian: Visudyne 15 mg prašak za otopinu za infuziju
English: This effect was not observed in conscious non-sedated pigs, or in any other species, including man. Verteporfin at more than 5 times the expected maximum plasma concentration in treated patients, caused a low level of complement activation in human blood in vitro.
Croatian: Verteporfin je in vitro, u koncentraciji više od 5 puta većoj od one najveće očekivane u plazmi liječenih bolesnika, izazvao samo slabo aktiviranje komplementa u ljudskoj krvi.
English: 7.5 ml of reconstituted solution contains 15 mg of verteporfin.
Croatian: 7,5 ml rekonstituirane otopine sadržava 15 mg verteporfina.
English: After single use the vial and any unused portion of reconstituted solution should be disposed of after single use in accordance with local requirements.
Croatian: Bočica i sva rekonstituirana otopina preostala nakon jednokratne uporabe trebaju se ukloniti u skladu s lokalnim propisima.
English: The subgroup of patients with predominantly classic CNV lesions (N=243; Visudyne 159, placebo 84) were more likely to exhibit a larger treatment benefit.
Croatian: Korist od liječenja bila je veća u skupini bolesnika s predominantno klasičnim lezijama CNV-a (N=243; Visudyne 159, placebo 84).
English: Dark green to black powder.
Croatian: Prašak za otopinu za infuziju Tamnozeleni do crni prašak.
English: Talk to your doctor, pharmacist or nurse before you are given Visudyne - If you experience any infusion-related problems or symptoms during or following the treatment such as chest pain, sweating, dizziness, rash, breathlessness, flushing, irregular heart beat or seizure, please tell your doctor or nurse immediately, as the infusion may need to be stopped and your condition may need to be treated urgently.
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primijenite Visudyne - Ako osjetite bilo kakve probleme vezano uz infuziju ili simptome tijekom ili nakon liječenja kao što su bol u prsnom košu, znojenje, omaglica, osip, zadihanost, navala crvenila,
English: One multicentre, double-masked, placebo-controlled, randomised study (BPD OCR 003 PM [VIPPM]) was conducted in patients with subfoveal choroidal neovascularisation caused by pathological myopia.
Croatian: Jedno je multicentrično, dvostruko slijepo, placebom kontrolirano, randomizirano kliničko ispitivanje (BPD OCR 003 PM [VIP-PM]) provedeno u bolesnika sa subfovealnom neovaskularizacijom žilnice izazvanom patološkom kratkovidnošću.
English: A total of 120 patients (81 Visudyne, 39 placebo) were enrolled in the study.
Croatian: Obuhvatilo je ukupno 120 bolesnika (81 je primao Visudyne, 39 ih je primalo placebo).
English: • General disorders: vasovagal reactions (fainting), sweating, flushing, or changes in blood pressure.
Croatian: • Opći poremećaji: zabilježene su vazovagalne rakcije (nesvjestica), znojenje, navalu crvenila ili promjene krvnog tlaka.
English: Lactose monohydrate Egg phosphatidylglycerol Dimyristoyl phosphatidylcholine Ascorbyl palmitate Butylated hydroxytoluene (E321)
Croatian: 6.1 Popis pomoćnih tvari laktoza hidrat fosfatidilglicerol iz jaja dimiristoilfosfatidilkolin askorbilpalmitat butilhidroksitoluen (E321)
English: The vial and any unused portion of reconstituted solution should be discarded after single use.
Croatian: Bočica i sva rekonstituirana otopina preostala nakon jednokratne uporabe trebaju se ukloniti.
English: Shelf-life after reconstitution and dilution: see package leaflet.
Croatian: Rok valjanosti nakon pripreme otopine za primjenu i razrjeđivanja: vidjeti uputu o lijeku.
English: In relation to TAP extension:
Croatian: Podaci o nastavku TAP kliničkog ispitivanja:
English: A maximum 2-fold inter-individual variation in plasma concentrations at Cmax (immediately after end of the infusion) and at the time of light administration was found for each Visudyne dose administered.
Croatian: Za svaku od primijenjenih doza Visudynea izmjereno je variranje vrijednosti koncentracije u plazmi različitih bolesnika za najviše dva puta pri Cmax (odmah nakon završetka infuzije) i u trenutku primjene svjetlosti.
English: 364 patients (244 verteporfin, 120 placebo) were enrolled in this study.
Croatian: U ovo ispitivanje upisano je 364 bolesnika (244 u skupinu liječenu verteporfinom, 120 u skupinu liječenu placebom).
English: The primary efficacy variable was responder rate, defined as the proportion of patients who lost less than 15 letters (equivalent to 3 lines) of visual acuity (measured with the ETDRS charts) at month 12 relative to baseline.
Croatian: Primarni pokazatelj djelotvornosti bila je stopa bolesnika s odgovorom, koja se definirala kao udio bolesnika čija se vidna oštrina (mjereno tablicom ETDRS) nakon 12 mjeseci smanjila za manje od 15 znakova (što je jednako 3 reda) u odnosu na početno stanje.
English: Patients should not drive or use machines as long as these symptoms persist.
Croatian: Sve dok simptomi traju, bolesnik ne smije upravljati vozilima ni raditi na strojevima.
English: Pathological myopia
Croatian: Patološka kratkovidnost
English: Hypercholesteraemia.
Croatian: Hiperkolesterolemija.
English: Visudyne 15 mg powder for solution for infusion verteporfin
Croatian: Visudyne 15 mg prašak za otopinu za infuziju verteporfin
English: Do not dissolve in sodium chloride solution.
Croatian: Ne otapati u otopini natrijeva klorida.
English: Lactose monohydrate, dimyristoyl phosphatidylcholine, egg phosphatidylglycerol, ascorbyl palmitate, butylated hydroxytoluene (E321).
Croatian: Laktoza hidrat, dimiristoilfosfatidilkolin, fosfatidilglicerol iz jaja, askorbilpalmitat, butilhidroksitoluen (E321).
English: Visudyne has not been studied in patients with renal impairment.
Croatian: Primjena Visudynea nije ispitivana u bolesnika s oštećenjem bubrega.
English: At month 12, there was a benefit of Visudyne for the primary efficacy endpoint (percentage of patients who lost less than 3 lines of visual acuity) - 86% for Visudyne versus 67% for placebo, p=0.011.
Croatian: Nakon 12 mjeseci uočena je korist od liječenja Visudyneom u smislu učinkovitosti kao primarnog ishoda (postotak bolesnika u kojih se vidna oštrina smanjila za manje od 3 retka) - uočeno je 86% odgovora u skupini koja je primala Visudyne, u usporedbi s 67% u skupini koja je primala placebo, p=0,011.
English: Metabolism and nutrition disorders Common
Croatian: Anafilaktička reakcija Poremećaji metabolizma i prehrane Često
English: It is recommended that reconstituted Visudyne be inspected visually for particulate matter and discoloration prior to administration.
Croatian: Preporučuje se vizualno pregledati rekonstituirani Visudyne prije primjene, kako bi se provjerilo da nema čestica ni promjene boje.
English: For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
Croatian: Uvjete čuvanja nakon rekonstitucije i razrjeđivanja lijeka vidjeti u dijelu 6.3. 6.5 Vrsta i sadržaj spremnika
English: Injection site pain, injection site oedema, injection site inflammation, injection site extravasation, asthenia.
Croatian: Bol na mjestu injiciranja, edem na mjestu injiciranja, upala na mjestu injiciranja, ekstravazacija mjesta injiciranja, astenija.
English: In such cases, the patient should prolong skin and eye protection from direct sunlight or bright indoor light for a period proportionate with the overdose given.
Croatian: U takvim se slučajevima, razmjerno predoziranju, mora produžiti i razdoblje zaštite kože i očiju od izravne sunčeve svjetlosti, kao i zaštite od jakog sobnog svjetla.
English: You should only be given Visudyne if your doctor considers it absolutely essential.
Croatian: Visudyne se smije koristiti samo uz suglasnost vašeg liječnika.
English: Visudyne should be administered only by ophthalmologists experienced in the management of patients with age-related macular degeneration or with pathological myopia.
Croatian: Visudyne smiju primjenjivati samo oftalmolozi s iskustvom u zbrinjavanju bolesnika sa senilnom makularnom degeneracijom (AMD - age-related macular degeneration) ili s patološkom kratkovidnošću.
English: Do not use sodium chloride solution.
Croatian: Otopina natrijeva klorida se ne smije koristiti.
English: in the treated eye. • General disorders: feeling unwell.
Croatian: • Opći poremećaji: lose osjećanje.
English: What Visudyne is used for Visudyne is used to treat the wet form of age-related macular degeneration and pathological myopia.
Croatian: Visudyne se koristi za liječenje vlažnog oblika senilne makularne degeneracije i patološke kratkovidnosti.
English: Prolonged exposure to light from light-emitting medical devices such as pulse oximeters should also be avoided for 48 hours following Visudyne administration.
Croatian: 48 sati nakon infuzije Visudyneom potrebno je izbjegavati i produženo izlaganje svjetlosti iz medicinskih proizvoda koji emitiraju svjetlost, npr. pulsnih oksimetara.
English: The first step is a 10-minute intravenous infusion of Visudyne at a dose of 6 mg/m body surface area,
Croatian: U prvom se koraku Visudyne daje u intravenskoj infuziji tijekom 10 minuta, u dozi od 6 mg/m tjelesne površine, razrijeđen u 30 ml infuzijske otopine (vidjeti dio 6.6).
English: Each vial contains 15 mg of verteporfin.
Croatian: Svaka bočica sadrži 15 mg verteporfina.
English: Infusion-related back and chest pain, which may radiate to other areas, including, but not limited to, the pelvis, shoulder girdle or rib cage.
Croatian: Uočena je i pojava boli u leđima povezana s primjenom infuzije te boli u prsnom košu koja se može širiti u druge dijelove tijela, uključujući zdjelicu, rameni obruč i rebra, no ne ograničavajući se samo na njih.
English: Respiratory, thoracic and mediastinal disorders Common
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja Često
English: There are no human fertility data for verteporfin.
Croatian: Nema podataka o učincima verteporfina na plodnost u ljudi.
English: The percentage of patients who lost less than 1.5 lines was 72% for Visudyne and 44% for placebo (p=0.003).
Croatian: Postotak bolesnika u kojih se vidna oštrina smanjila za manje od 1,5 redaka iznosio je 72% u skupini koja je primala Visudyne i 44% u skupini koja je primala placebo (p=0,003).
English: The posology and retreatments were the same as in the AMD studies.
Croatian: Doziranje i način primjene lijeka bili su jednaki kao i u ispitivanju bolesnika s AMD-om.
English: Retinal detachment, retinal haemorrhage, vitreous haemorrhage, retinal oedema.
Croatian: Odvajanje mrežnice, retinalno krvarenje, krvarenje u staklovinu, edem mrežnice.
English: At month 24, 79% Visudyne patients versus 72% placebo patients had lost less than 3 lines of visual acuity (p=0.38).
Croatian: Nakon 24 mjeseca vidna se oštrina smanjila za manje od 3 retka u 79% bolesnika koji su primali Visudyne i u 72% onih koji su primala placebo (p=0,38).
English: Injection site vesicles, injection site necrosis.
Croatian: Vezikule na mjestu injiciranja, nekroza na mjestu primjene injekcije.
English: Visudyne therapy should be considered carefully in patients with moderate hepatic dysfunction or biliary obstruction.
Croatian: Moguću primjenu Visudynea u bolesnika s umjerenom disfunkcijom jetre ili bilijarnom opstrukcijom potrebno je pažljivo razmotriti.
English: There were no teratogenic effects observed in rabbits at doses up to 10 mg/kg/day (approximately 20-fold human exposure at 6 mg/m based on body surface area).
Croatian: U kunića pri dozama od najviše 10 mg/kg/dan (približno 20 puta većim od izloženosti u ljudi od 6 mg/m tjelesne površine) nisu zapaženi teratogeni učinci.
English: Eye disorders Common
Croatian: Poremećaji oka Često
English: By itself, the clinically recommended dose of verteporfin is not cytotoxic.
Croatian: Verteporfin sam po sebi nije citotoksičan u klinički preporučenoj dozi.
English: • General disorders: rash, hives, itching
Croatian: • Opći poremećaji: osip, urtikarija, svrbež
English: Other photosensitising agents
Croatian: Ostali lijekovi koji izazivaju fotosenzibilnost
English: Each vial contains 15 mg of verteporfin
Croatian: Jedna bočica sadržava 15 mg verteporfina
English: Injection site hypersensitivity, injection site haemorrhage, injection site discoloration, pyrexia, pain.
Croatian: Preosjetljivost na mjestu injiciranja, krvarenje na mjestu injiciranja, promjena boje kože na mjestu injiciranja, pireksija, bol.
English: - If you experience any eye problems after the treatment, such as a vision loss, talk to your doctor.
Croatian: - Ako nakon liječenja imate bilo kakvih problema, o tome obavijestite svog liječnika.
English: 5, infusion-related reaction primarily presented as back pain
Croatian: 5, reakcija povezana s infuzijom koja se primarno javlja kao bol u leđima Zabilježene su vazovagalne reakcije i reakcije preosjetljivosti vezano uz infuziju Visudynea.
English: 1 vial of powder.
Croatian: Prašak za otopinu za infuziju 1 bočica s praškom.
English: - The other ingredients are dimyristoyl phosphatidylcholine, egg phosphatidylglycerol, ascorbyl palmitate, butylated hydroxytoluene (E321) and lactose monohydrate.
Croatian: - Drugi sastojci su dimiristoilfosfatidilkolin, fosfatidilglicerol iz jaja, askorbilpalmitat,
English: VIAL LABEL
Croatian: KARTONSKA KUTIJA
English: No additional monitoring is required.
Croatian: Nije potrebno dodatno praćenje.
English: (See section 4.5)
Croatian: (Vidjeti dio 4.5)
English: However, toxicity to reproduction has not been reported.
Croatian: Međutim nije zabilježena reproduktivna toksičnost.
English: Combination with beta-blockers
Croatian: Kombinacija s beta-blokatorima
English: This medicine will be given to you in hospital.
Croatian: Ovaj ćete lijek primiti u bolnici.
English: Other common side effects (these may affect up to 1 in 10 people) are:
Croatian: Druge česte nuspojave (mogu se javiti u do 1 na 10 osoba) su:
English: Continue blood pressure monitoring until desired effect is achieved.
Croatian: Nastavite pratiti krvni tlak dok se ne postigne željeni učinak.
English: Like all medicines, this medicine can cause side effects, although not everybody gets them.
Croatian: Kao i svi drugi lijekovi, ovaj lijek može uzrokovati nuspojave iako se one neće razviti kod svakoga.
English: This includes medicines obtained without a prescription and herbal medicines.
Croatian: To uključuje i lijekove dobivene bez recepta i biljne lijekove.
English: Headache is the most common side effect, and may affect more than 1 in 10 people.
Croatian: Glavobolja je najčešća nuspojava i može se javiti u više od 1 na 10 osoba.